Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American patients
Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US
With over 15 years of hands-on experience in Diagnostic Imaging and Sales, Robyn will be solidifying our presence in the Western US. Robyn has an extensive background in Diagnostic Imaging including Nuclear Medicine, Positron Emission Tomography (P.E.T.) and Radiologic Technology. She began her career in the clinical setting as a Radiologic Technologist specializing in Computed Tomography (CT), Mammography and expanding her training at Loma Linda Medical University in Nuclear Medicine Technology.
Anthony Zinno, MBA Joins Telix Pharmaceuticals US
With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success has been built on developing and implementing business strategies, scaling and structuring organizations for growth, and developing unified cultures focused on common goals.
NDA Clinical Briefing Package Submitted to the US FDA
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1
ZIRCON Phase 3 IND Submitted to the US FDA
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx
TLX101 for Brain Cancer IPAX-1 Study Update
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research grant
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s Molecularly Targeted Radiation (MTR) intellectual property for the treatment of non-muscle invasive bladder cancer that is resistant to standard therapies.
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Telix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference.
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which in 2018, hosted 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.